Michael Landsberg

Dr. Michael Landsberg

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2021 in Neuron
Verified
Journal Article
Closed access
MFMatthew D. Figley
Matthew D. Figley
WGWeixi Gu
Weixi Gu
JNJeffrey D. Nanson
Jeffrey D. Nanson
YSYun Shi
Yun Shi
YSYo Sasaki
Yo Sasaki
TVThomas Ve
Thomas Ve

31 July 2017 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
TVThomas Ve
Thomas Ve
PVParimala R Vajjhala
Parimala R Vajjhala
AHAndrew Hedger
Andrew Hedger
TCTristan Croll
Tristan Croll
FDFrank DiMaio
Frank DiMaio
BKBostjan Kobe
Bostjan Kobe

30 September 2022 in Science
Verified
Journal Article
Closed access
MMMohammad K. Manik
Mohammad K. Manik
YSYun Shi
Yun Shi
SLSulin Li
Sulin Li
MZMark A. Zaydman
Mark A. Zaydman
NDNeha Damaraju
Neha Damaraju
BKBostjan Kobe
Bostjan Kobe
Cyclic adenosine diphosphate (ADP)–ribose (cADPR) isomers are signaling molecules produced by bacterial and plant Toll/interleukin-1 receptor (TIR) domains via nicotinamide adenine dinucleotide (oxidized form) (NAD + ) hydrolysis. We show that v-cADPR (2′cADPR) and v2-cADPR (3′cADPR) isomers are cyclized by O-glycosidic bond formation between the ribose moieties in ADPR. Structures of 2′cADPR-producing TIR domains reveal conformational changes that lead to an active assembly that resembles those of Toll-like receptor adaptor TIR domains. Mutagenesis reveals a conserved tryptophan that is essential for cyclization. We show that 3′cADPR is an activator of ThsA effector proteins from the bacterial antiphage defense system termed Thoeris and a suppressor of plant immunity when produced by the effector HopAM1. Collectively, our results reveal the molecular basis of cADPR isomer production and establish 3′cADPR in bacteria as an antiviral and plant immunity–suppressing signaling molecule.

4 August 2013 in Nature
Verified
Journal Article
Closed access
PDF file
JBJason N. Busby
Jason N. Busby
Santosh PanjikarSantosh Panjikar
Santosh Panjikar
MLMichael Landsberg
Michael Landsberg
MHMark Hurst
Mark Hurst
JLJ. Shaun Lott
J. Shaun Lott

8 January 2021 in Science
Verified
Journal Article
Closed access
PDF file
NMNaphak Modhiran
Naphak Modhiran
HSHao Song
Hao Song
LLLidong Liu
Lidong Liu
CBCheryl Bletchly
Cheryl Bletchly
LBLou Brillault
Lou Brillault
DWDaniel Watterson
Daniel Watterson
Two antibodies against flaviviruses: Flaviviruses are a group of RNA viruses that include the human pathogens dengue virus, Zika virus, and West Nile virus. The envelope protein (E) on the virus surface has been the target of vaccine development, but problems have arisen with antibodies against E, leading to enhanced infection. Now, Modhiran et al. and Biering et al. describe two different antibodies that bind to the flavivirus NS1 protein and prevent it from disrupting epithelial cells, which is associated with severe disease. Both antibodies cross-react with multiple flavivirus NS1 proteins. The antibodies reduce viremia and increase survival in mouse models of flavivirus disease. Both papers include structures of NS1 bound to an antibody, which give insight into the protective mechanism. Science , this issue p. 190 , p. 194

1 September 2016 in Renewable and Sustainable Energy Reviews
Verified
Journal Article
Closed access
ARAndrew K. Ringsmuth
Andrew K. Ringsmuth
MLMichael Landsberg
Michael Landsberg
BHBen Hankamer
Ben Hankamer